|1.||Belardinelli, Luiz: 3 articles (01/2009 - 05/2006)|
|2.||Dhalla, Arvinder K: 3 articles (01/2009 - 05/2006)|
|3.||Reaven, G M: 1 article (02/2009)|
|4.||Dhalla, A K: 1 article (02/2009)|
|5.||Belardinelli, L: 1 article (02/2009)|
|6.||Santikul, M: 1 article (02/2009)|
|7.||Chisholm, J W: 1 article (02/2009)|
|8.||Severson, David L: 1 article (01/2009)|
|9.||Shearer, Jane: 1 article (01/2009)|
|10.||Su, Lin: 1 article (01/2009)|
05/01/2007 - "The present study was undertaken to determine the effect of CVT-3619 on insulin resistance induced by high-fat (HF) diet in rodents. "
02/01/2009 - "The antilipolytic effects of CVT-3619 appear to be independent of insulin resistance and animal model."
01/01/2009 - "Results show that the acute administration of CVT-3619 lowers circulating fatty acid levels, leading to improved whole-body and cardiac glucose clearance in a model of diet-induced insulin resistance. "
02/01/2009 - "Our previous observation that CVT-3619 lowered plasma FFA and triglyceride concentrations in rats and enhanced insulin sensitivity in rodents with dietary-induced forms of insulin resistance suggested that it might be of use in the treatment of patients with 2DM. "
05/01/2007 - "In conclusion, CVT-3619 treatment lowers FFA and TG concentrations and improves insulin sensitivity in rodent models of insulin resistance."
05/01/2006 - "CVT-3619 did not change atrial rate in rat heart and caused a small (6-ms) prolongation of the stimulus-to-His bundle interval without causing atrioventricular block in guinea pig heart (effects mediated by A(1)AdoR), whereas CPA caused atrioventricular block and near cessation of atrial electrical activity. "
12/01/2008 - "Intense efforts by many pharmaceutical companies and academicians in the A(1)-AdoR agonist field have led to the discovery of clinical candidates for the following conditions: atrial arrhythmias - Tecadenoson, Selodenoson and PJ-875; type 2 diabetes (T2D) and insulin-sensitizing agents - GR79236, ARA, and CVT-3619; pain management - SDZ WAG 994, GW493838; and angina - BAY-68-4986. "
|5.||N- ((1S,trans)- 2- hydroxycyclopentyl)adenosine